{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:26:06Z","timestamp":1773422766478,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,24]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Guselkumab has been shown to be safe and effective for the treatment of psoriasis in numerous randomized clinical trials and real-life studies. Real-life data on treatment up to 4\u2005years are lacking.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n The present study aims to estimate the drug survival, effectiveness and safety of guselkumab over a period of 208 weeks.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We included all consecutive patients with psoriasis or psoriatic arthritis receiving at least one dose of guselkumab. Effectiveness was evaluated as achieving 100% or \u2265 90% improvement in the Psoriasis Area and Severity Index (PASI 100 or PASI 90) and absolute PASI \u2264 3. Drug survival was evaluated using the Kaplan\u2013Meyer curves.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In total, 202 patients were studied. Their mean PASI decreased from 10.9 (SD 5.76) at baseline to 0.48 at week 208. Rates of PASI 100 response improved over time: the outcome was achieved in 30.0% and 65% of patients at weeks 16 and 208, respectively. For PASI 90 and PASI \u2264 3 we found similar trends. After 208 weeks of treatment, the estimated rate of drug survival was 68.5% in observed cases. Being super responders (SRs) according to our definition (P = 0.005) and the GUIDE definition (P &lt; 0.001) reduced the risk of drug interruption, as did cardiovascular comorbidities. In our population, none of the baseline characteristics showed a clear impact on the effectiveness of guselkumab. Considering both SR definitions, in our cohort, being an SR was associated with a better response in the long term when considering PASI 100 and 90 in both linear and multivariate analyses.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our study confirms the good effectiveness and favourable safety profile of guselkumab in a real-world setting up to 4\u2005years.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/ced\/llaf010","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T03:27:41Z","timestamp":1736306861000},"page":"1590-1597","source":"Crossref","is-referenced-by-count":5,"title":["Drug survival, effectiveness and safety of guselkumab for moderate-to-severe psoriasis for up to 4\u2005years"],"prefix":"10.1093","volume":"50","author":[{"given":"Luca","family":"Mastorino","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin , Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin , Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin , Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Stroppiana","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin , Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Verrone","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin , Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Astrua","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin , Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Fiasconaro","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin , Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin , Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Gallo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin , Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin , Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin , Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"2025072412174208000_llaf010-B1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025072412174208000_llaf010-B2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025072412174208000_llaf010-B3","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"2025072412174208000_llaf010-B4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025072412174208000_llaf010-B5","first-page":"e15670","article-title":"Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study","volume":"35","author":"Mastorino","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025072412174208000_llaf010-B6","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1080\/14712598.2022.2064216","article-title":"Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience","volume":"22","author":"Bardazzi","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2025072412174208000_llaf010-B7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s13555-023-00893-4","article-title":"Long-term efficacy, safety, and drug survival of guselkumab in patients with psoriasis: real-world data from the Czech Republic BIOREP registry","volume":"13","author":"Hugo","year":"2023","journal-title":"Dermatol Ther (Heidelb"},{"key":"2025072412174208000_llaf010-B8","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2147\/CCID.S364640","article-title":"Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025072412174208000_llaf010-B9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19296","article-title":"Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: week 104 results from the non-interventional, prospective, German multicentre PERSIST study","author":"Gerdes","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025072412174208000_llaf010-B10","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.3390\/jcm13092552","article-title":"Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 3-year multicenter study","volume":"13","author":"Megna","year":"2024","journal-title":"J Clin Med"},{"key":"2025072412174208000_llaf010-B11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/14712598.2023.2194485","article-title":"Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks","volume":"23","author":"Galluzzo","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2025072412174208000_llaf010-B12","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025072412174208000_llaf010-B13","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/exd.14731","article-title":"\u2018Superresponders\u2019 at biologic treatment for psoriasis: a comparative study among IL17 and IL23 inhibitors","volume":"32","author":"Mastorino","year":"2023","journal-title":"Exp Dermatol"},{"key":"2025072412174208000_llaf010-B14","doi-asserted-by":"crossref","first-page":"632","DOI":"10.36849\/JDD.7486","article-title":"Real-life effectiveness and safety of guselkumab in moderate-to-severe plaque psoriasis: a 104-week retrospective single-center study","volume":"23","author":"Gargiulo","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"2025072412174208000_llaf010-B15","first-page":"34","article-title":"Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment","volume":"22","author":"Mastorino","year":"2024","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"2025072412174208000_llaf010-B16","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1111\/jdv.19599","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study: an analysis with considerations for future studies","volume":"38","author":"Javaid","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025072412174208000_llaf010-B17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-week versus 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial","volume":"160","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2025072412174208000_llaf010-B18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdin.2021.05.003","article-title":"Drug survival of guselkumab in patients with plaque psoriasis: a 2\u2005year retrospective, multicenter study","volume":"4","author":"Lytvyn","year":"2021","journal-title":"JAAD Int"},{"key":"2025072412174208000_llaf010-B19","doi-asserted-by":"crossref","first-page":"1341708","DOI":"10.3389\/fimmu.2023.1341708","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses \u2013 IL PSO (Italian landscape psoriasis)","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Front Immunol"},{"key":"2025072412174208000_llaf010-B20","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1111\/jdv.19135","article-title":"Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients","volume":"37","author":"Mastorino","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025072412174208000_llaf010-B21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/ijd.17038","article-title":"Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3\u2005years","volume":"63","author":"Mastorino","year":"2024","journal-title":"Int J Dermatol"},{"key":"2025072412174208000_llaf010-B22","doi-asserted-by":"crossref","first-page":"adv00821","DOI":"10.2340\/actadv.v102.1982","article-title":"Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a tertiary care centre in Northern Italy","volume":"102","author":"Mastorino","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2025072412174208000_llaf010-B23","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.3390\/jcm13216401","article-title":"Psoriasis in childbearing age: a real-life, retrospective, single-center study on anti-IL17 and IL-23 agents","volume":"13","author":"Borriello","year":"2024","journal-title":"J Clin Med"},{"key":"2025072412174208000_llaf010-B24","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.3390\/jcm13216546","article-title":"Drug survival and clinical course of patients with cancer treated with biologic therapy for psoriasis","volume":"13","author":"Macagno","year":"2024","journal-title":"J Clin Med"},{"key":"2025072412174208000_llaf010-B25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0846.2007.00218.x","article-title":"Tape-stripping method in man: comparison of evaporimetric methods","volume":"13","author":"Zhai","year":"2007","journal-title":"Skin Res Technol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf010\/61372719\/llaf010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/8\/1590\/61372719\/llaf010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/8\/1590\/61372719\/llaf010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T16:17:51Z","timestamp":1753373871000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/8\/1590\/7945321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,1,8]]},"published-print":{"date-parts":[[2025,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf010","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,1,8]]}}}